Negative in Ames, in vitro mouse lymphoma and in vivo rat micronucleus assays
“Odevixibat tested negative in the bacterial reverse mutation (Ames) assay, the in vitro mouse lymphoma cell forward mutation assay, and the in vivo rat micronucleus test.”
Rat fertility and EFD: no adverse findings; rabbit EFD: cardiovascular fetal malformations at all doses
“No adverse findings were observed in the fertility study in male and female Wistar rats, the embryo-fetal development study in rats, or the juvenile toxicity study in rats. In an embryo-fetal development study in pregnant rabbits, fetuses from all maternal groups treated orally with odevixibat showed an increase in cardiovascular malformations”
No concerns in cardiovascular, respiratory, CNS, gastrointestinal or renal safety pharmacology studies
“There were no nonclinical safety issues of significant concern as assessed by the secondary pharmacology screens or the cardiovascular, respiratory, central nervous system, gastrointestinal, or renal safety pharmacology studies conducted during the development program.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative